Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study

• DOI: 10.3390/brainsci11030316
• Publication Date: 2021-03-03T02:24:01Z
• Authors: Diego Santos García; Carmen Labandeira...; Rosa Yáñez Baña; Maria Icíar Cimas...; Iria Cabo López; Jose Manuel Paz G...; Maria Gemma Alons...; María José Gonzál...; Cristina Martínez...
• Keywords: Apathy

Some studies observed a benefit of Parkinson's disease (PD) patients after treatment with safinamide in some non-motor symptoms (NMSs). The aim this study was to analyze the effectiveness on NMS burden PD. SAFINONMOTOR (an open-label patients) is prospective single-arm conducted five centers from Spain. primary efficacy outcome change baseline (V1) end observational period (6 months) (V4) scale (NMSS) total score. Between May/2019 and February/2020 50 were included (age 68.5 ± 9.12 years; 58% females; 6.4 5.1 years diagnosis). At 6 months, 44 completed follow-up (88%). NMSS score reduced by 38.5% (from 97.5 43.7 V1 59.9 35.5 V4;